Citations 1
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia
Propert, Kathleen J., Loren, Alison W. , Paietta, Elisabeth , Sun, Zhuoxin , Levine, Ross L. , Straley, Kimberly, Yen, Katharine , Patel, Jay P., Agresta, Samuel , Abdel‐Wahab, Omar , Perl, Alexander E. , Litzow, Mark R. , Rowe, Jacob M. , Fernández, Hugo F. , Margolis, David J. , Tallman, Martin S. , Luger, Selina M. , DiNardo, Courtney D. , Lazarus, Hillard M. , Carroll, Martin P , Abdel-Wahab, Omar
Blood | May 3, 2013 | Volume: 121 | Issue: 24 | Pages: 4917-4924
Key Points Serum 2HG analysis by LC-MS can accurately identify patients with AML with and without IDH mutations. Oncometabolite testing of serum 2HG is indicated as a diagnostic, prognostic, and therapeutic monitoring tool in AML.